Sinopharm Tech Holdings Limited (8156) AI Stock Analysis

Sinopharm Tech Holdings Limited

(HKEX:8156)

Select Model

Rating:45Neutral

Price Target:HKD 0.19▼(-2.58% Downside)

Action:reiterated

Date:10/16/26

The score is primarily held down by very weak financial performance—sharp revenue decline, ongoing losses, negative equity, and negative recent free cash flow. Technicals offer some near-term stabilization (price above shorter moving averages and RSI in the low 60s), but the longer-term trend remains soft (below the 200-day average) and valuation signals are not supportive given loss-making earnings.

Positive Factors

Debt reductionLower total debt than in prior years is a constructive balance-sheet trend and may reduce future financing pressure if maintained. However, the benefit is limited because debt remains meaningful relative to assets and the company continues to have negative shareholders’ equity.

Negative Factors

Sharp revenue contractionA revenue decline of roughly half in one year materially weakens operating scale and reduces the base from which the company can generate earnings. The reversal after a 2025 rebound also signals unstable demand or business activity, limiting confidence in near-term revenue visibility.

Sinopharm Tech Holdings Limited (8156) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 114.06M
Dividend Yield: ―
Average Volume (3M): 53.52K
Price to Earnings (P/E): -7.4
Beta (1Y): 0.32
Revenue Growth: -25.58%
EPS Growth: -12.50%
Country: Hong Kong
Employees: 31
Sector: Technology
Sector Strength: 61
Industry: Software - Application

Sinopharm Tech Holdings Limited Business Overview & Revenue Model

Company Description

Sinopharm Tech Holdings Limited functions as an investment holding enterprise, with its primary focus on lottery operations across mainland China and Hong Kong. The company diversifies its activities into several key areas: it supplies both hardware...

Sinopharm Tech Holdings Limited Financial Statement Overview

Summary

Overall financials are very weak: revenue fell sharply in 2026 (~49.5% YoY) and the company remains loss-making with low gross margin (~14.1%) and negative EBIT/EBITDA and net margin (~-20.1%). The balance sheet is the biggest risk with persistently negative shareholders’ equity (e.g., -46.4M in 2026) and meaningful debt relative to assets. Cash flow is also unstable, with negative operating and free cash flow in 2026 (-4.0M), limiting self-funding capacity.

Income Statement

24Negative

Balance Sheet

10Very Negative

Cash Flow

22Negative

Financial statement breakdown
Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	78.53M	45.58M	61.25M	41.28M	42.84M	40.98M
Gross Profit	13.60M	6.42M	13.52M	5.02M	5.47M	5.10M
EBITDA	2.75M	-6.94M	6.11M	4.98M	-1.01M	-75.17M
Net Income	-1.77M	-9.14M	-867.00K	-19.70M	-10.63M	-88.00M
Balance Sheet
Total Assets	22.44M	22.44M	51.74M	44.49M	33.48M	76.89M
Cash, Cash Equivalents and Short-Term Investments	5.62M	5.62M	6.95M	2.64M	1.78M	2.99M
Total Debt	30.73M	30.73M	46.73M	73.26M	53.00M	45.93M
Total Liabilities	71.32M	71.32M	88.43M	250.09M	213.24M	250.28M
Stockholders Equity	-46.40M	-46.40M	-36.87M	-199.48M	-172.73M	-166.78M
Cash Flow
Free Cash Flow	-3.48M	-4.02M	-7.21M	-12.58M	4.73M	-36.88M
Operating Cash Flow	-5.93M	-4.02M	-7.21M	-9.25M	4.73M	-36.76M
Investing Cash Flow	-8,000	2,000	-9,000	-4.86M	2,000	-85.00K
Financing Cash Flow	12.01M	3.07M	11.50M	14.98M	-4.52M	32.24M

Sinopharm Tech Holdings Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price0.19

Price Trends

50DMA0.19Negative

100DMA0.19Positive

200DMA0.23Negative

Market Momentum

MACD-0.00Negative

RSI48.92Neutral

STOCH49.05Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8156, the sentiment is Negative. The current price of 0.19 is above the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.19, and below the 200-day MA of 0.23, indicating a bearish trend. The MACD of -0.00 indicates Negative momentum. The RSI at 48.92 is Neutral, neither overbought nor oversold. The STOCH value of 49.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8156.

Sinopharm Tech Holdings Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

HK:8156 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:9885	69Neutral	HKD 2.35B	10.81	7.63%	3.63%	16.99%	126.15%
HK:2571	68Neutral	HKD 2.17B	344.01	0.76%	―	-2.29%	-91.48%
Sector *	61Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
HK:2576	54Neutral	HKD 2.33B	-30.39	-5.91%	―	―	―
HK:8148	50Neutral	HKD 1.49B	82.44	21.60%	―	151.97%	―
HK:8156	45Neutral	HKD 122.94M	-7.38	20.88%	―	-25.58%	-12.50%

* Technology Sector Average

Performance Comparison

HK:8156 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:8156	Sinopharm Tech Holdings Limited	0.19	-0.11	-35.33%
HK:8148	Aurum Pacific (China) Group Ltd.	3.25	1.22	60.10%
HK:9885	YSB Inc.	3.44	-5.64	-62.10%
HK:2576	Zhejiang Taimei Medical Technology Co Ltd Class H	4.14	-0.28	-6.33%
HK:2571	Beijing Saimo Technology Co. Ltd. Class H	16.25	3.41	26.56%
HK:6687	JST Group Corporation Limited	9.85	-24.79	-71.56%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 16, 2026

Sinopharm Tech Holdings Limited AI Stock Analysis